CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain
CEL-SCI Corporation("CEL SCI" or the "Company") today announced that Spain's Agency for Medicinal Products and Medicinal Devices has authorized the Company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Spain is the 22nd country to authorize CEL-SCI's Phase 3 trial for patient enrollment.
View full press release